stockrowLegend Biotech Corporation Sponsored ADR
LEGN Healthcare Biotechnology
Legend Biotech Corporation Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.0 billion, up 64.0% from fiscal 2024.
- Revenue
- +51.9%
- EPS
- +126.1%
- Free cash flow
- −26.8%
- Total debt
- −49.6%
Quarter to June 2026, against a year earlier
Follow LEGN
Alert me
Legend Biotech Corporation Sponsored ADR (LEGN) Revenue growth
Legend Biotech Corporation Sponsored ADR's revenue growth over the twelve months to 30 June 2026 was 59.6%, down 4.5 percentage points from fiscal 2025 (64.0%). Over the past ten years it has ranged from −52.0% (fiscal 2017) to 167.2% (fiscal 2018); the current reading is higher than 56% of that period. That is above the Biotechnology industry median of 6.76% and above the Healthcare sector median of 7.98%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 64.0% | (55.97) |
| FY2024 | 120.0% | (23.71) |
| FY2023 | 143.7% | 73.70 |
| FY2022 | 70.0% | 85.86 |
| FY2021 | −15.9% | (42.89) |
| FY2020 | 27.0% | 24.88 |
| FY2019 | 2.15% | (165.01) |
| FY2018 | 167.2% | 219.14 |
| FY2017 | −52.0% | — |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Jun 2026 | 51.9% | (4.56) |
| Mar 2026 | 56.5% | (7.80) |
| Dec 2025 | 64.3% | (5.73) |
| Sep 2025 | 70.0% | (101.42) |
| 23 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| COGT Cogent Biosciences, Inc. compare | 110.2% |
| LEGN Legend Biotech Corporation Sponsored ADR | 59.6% |
| TVTX Travere Therapeutics, Inc. compare | 49.4% |
| DNTH Dianthus Therapeutics, Inc. compare | −11.7% |
| CRSP CRISPR Therapeutics AG compare | −34.3% |
| RLAY Relay Therapeutics, Inc. compare | −74.3% |
| EWTX Edgewise Therapeutics, Inc. compare | — |
| DFTX Definium Therapeutics, Inc. compare | — |
| ERAS Erasca, Inc. compare | — |
| Biotechnology industry median | 6.76% |
| Healthcare sector median | 7.98% |
| Market median | 7.71% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on LEGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement